The fight against outdated Indonesian medical cannabis laws is being led by a mother as she struggles to get much-needed cannabis for her sick son. And while a previous application to the country's constitutional court in 2020 was rejected, the government has promised to review its current position. For now, cannabis remains a Class 1 narcotic, along with heroin, cocaine, and 65 other types.
Indonesian medical cannabis reform has resurfaced after a mother named Santi openly requested medical cannabis legalization as she fights for her son Pika. He has Japanese encephalitis, a viral disease transmitted by mosquito bites.
Santi Warastuti and two other women had previously submitted a court petition to review Indonesia’s Narcotics Law to the country’s Constitutional Court in November 2020. However, the court did not grant it.
“This medical cannabis is urgent for me because Pika, my child, is still not free from his seizures,” Santi said on the sidelines of a protest last week. A picture with a “Help my son get medical cannabis” sign has gone viral on Indonesian social media.
Pika would need CBD oil, which is still illegal in Indonesia. Cannabis for medical use conflicts with Law No. 35/2009 on narcotics.
Article 8, paragraph 1 of this law clearly explains that the use of class I narcotics in Indonesia, including cannabis, is prohibited, even in health care.
Research on Class I drugs can also only be carried out after obtaining the Minister’s approval on the recommendation of the head of the Indonesian Food and Drugs Control Agency. In these regulations, cannabis is included as a class I narcotic along with heroin, cocaine, opium, cocaine leaf, cathinone, ecstasy, and 65 other types.
Government policy is based on the United Nations decision to include cannabis in Schedule IV of the Single Convention on Narcotic Drugs of 1961.
However, changes took place in December 2020. The United Nations Commission on Narcotic Drugs (CND) removed cannabis from this list, which could start a change in Indonesia.
The discussions around legalizing medical cannabis in Indonesia returned to the carpet at the end of May. A commission has questioned the government’s attitude towards narcotics for medical purposes.
Asrul Sani, a member of Commission III of the Indonesian House of Representatives, admitted to receiving many suggestions from the public regarding the use of cannabis for medical purposes.
“We cannot deny that, to some extent, cannabis can be part of medicine. But, to what extent is the government going to open the space for this?” asked Asrul.
In 2017, Fidelis Arie Sudewarto, a civil servant, was arrested for planting 39 cannabis plants by the National Narcotics Agency (BNN).
The cannabis was grown to treat his wife, Yeni Riawati, diagnosed with syringomyelia, the growth of cysts in the spinal cord. His wife eventually died 32 days after the BNN arrested Fidelis.
Responding to this statement, the Deputy Minister of Law and Human Rights, Eddy OS Hiariej, said that the purpose of the Narcotics Act was not only to eradicate drug trafficking but also to guarantee the availability of narcotics for research and health.
“That means there is a health aspect here, so it is possible that, for example, cannabis for medical use could be used.”
In an interview, Deputy Chairman of Committee III of the Indonesian House of Representatives, Desmond Junaidi Mahesa, said on June 28 that he would consider the proposed revision of the Narcotics Law No. 35/2009 to eventually legalize medical cannabis.
“We will first look at the value of benefits and harms. From the studies I know of, it turns out that the value of the health and economic benefits is extraordinary, and the harms are very low,” Desmond said.
—
(Featured image by Andini Aisyah Hariadi via Twitter)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published by Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions, or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The DEA has postponed a key hearing on the reclassification of cannabis. The hearing was…
A new California Department of Public Health report has come out with recommendations for THC…
Ontario is investing $31 million over the next three years to enhance efforts against illegal…
Frankfurt and Hanover are launching five-year pilot projects for legal, regulated cannabis sales to adults,…
Italy's Regional Administrative Court suspended the Health Ministry's decree labeling CBD as a narcotic, pending…
This November, five U.S. states will vote on measures related to legalizing recreational or medical…